Stephan Grant, Ph.D.
Member, WRD Postdoctoral Program Governance Team
Undergraduate: B.S. Chemistry, University of Rhode Island
Graduate: Ph.D. Organic Chemistry, Texas A&M University
Postdoctoral Training: GlaxoSmithKline
I lead the Biochemistry and Primary Screening group in the Pfizer Oncology Research Unit in La Jolla, CA. My research group provides primary in vitro pharmacology support for preclinical cancer research projects, including drug discovery efforts on protein kinase inhibitors. A chemist by training, I am especially interested in the biochemical mechanisms of enzyme inhibition and how enzyme kinetics and conformational energetics can be leveraged to design new inhibitors as potential anti-cancer drugs.
Grant, S. Precision Medicine and the Development of Targeted Kinase Inhibitors for Cancer Patients. International Drug Discovery, 6, 24-28 (2011).
Grant SK and Lunney EA. Kinase Inhibition That Hinges on Halogen Bonds. Chemistry & Biology, 18, 3-4 (2011).
Grant S, Tran P, Zhang Q, et al. Discovery of a Novel Class of Targeted Kinase Inhibitors that Blocks Protein Kinase C Signaling and Ameliorates Retinal Vascular Leakage in a Diabetic Rat Model. Eur J Pharmacol, 627, 16-25 (2010).
Grant SK. Therapeutic Protein Kinase Inhibitors. Cell Mol Life Sci, 66, 1163-1177 (2009).
- « Robert T. Abraham, Ph.D.
- « Kim Arndt, Ph.D.
- « Bijan Boldajipour, Ph.D.
- « Javier Chaparro-Riggers, Ph.D.
- « Marc Damelin, Ph.D.
- « Christina Eng, Ph.D.
- « Max Follettie, Ph.D.
- « Kenneth Geles, Ph.D.
- « Stephan Grant, Ph.D.
- « Frank Loganzo, Ph.D.
- « Anthony Mazurek, Ph.D.
- « Brion W. Murray, Ph.D.
- « Robert A. Rollins, Ph.D.
- « Puja Sapra, Ph.D.
- « Michael A. White, Ph.D.